[Efficacy of ubidecarenone in the treatment of patients with cardiac insufficiency].
In 11 patients suffering from medium to severe heart failure, we performed a clinical and instrumental study to evaluate the effectiveness of ubidecarenone (60 mg/die in a single oral dose), in addition to conventional treatment with digitalis and diuretics. After an 8-month follow-up in most patients we observed a significant improvement in clinical symptoms and in quality of life. Furthermore we were able to demonstrate a statistically significant decrease in left atrium dimensions (p less than 0.01), end-diastolic (p less than 0.01) and end-systolic (p less than 0.05) left ventricular diameters and a significative reduction in the distance of the septum from the e point of the mitral valve (p less than 0.05), expression of significant improvement of cardiac output.
P L
PL
Topi
A
A
Davini
G
G
Squarcini
D000368:Aged; D000369:Aged, 80 and over; D002302:Cardiac Output; D003067:Coenzymes; D004341:Drug Evaluation; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000627:therapeutic use
D003067:Coenzymes; D014451:Ubiquinone; C024989:coenzyme Q10
Efficacia dell'ubidecarenone nel trattamento di pazienti affetti da insufficienza cardiaca.